OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:07:58 04/05/2024 am IST | ||
| 20.14 EUR | +0.45% |
|
| Current month | +2.91% | ||
| 1 month | -3.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 20.14 | +0.45% | 0 |
| 02/24/02 | 20.05 | +2.45% | 0 |
| 30/24/30 | 19.57 | -0.25% | 0 |
| 29/24/29 | 19.62 | -1.21% | 0 |
| 26/24/26 | 19.86 | +0.05% | 0 |
Delayed Quote Börse Stuttgart
Last update May 04, 2024 at 01:07 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | CP7DGN |
| ISIN | DE000CP7DGN7 |
| Date issued | 08/03/2019 |
| Strike | 186.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.6 € |
|---|---|
| Lowest since issue | 1.85 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
401.1
USD
Average target price
460.2
USD
Spread / Average Target
+14.75%
- Stock Market
- Certificates
- Certificat
